CAS: 218600-44-3; (4As,6Ar,6Bs,8Ar,12As,14Ar,14Bs)-11-Cyano-2,2,6A,6B,9,9,12A-Heptamethyl-10,14-Dioxo-1,3,4,5,6,6A,6B,7,8,8A,9,10,12A,14,14A,14B-Hexadecahydropicene-4A(2H)-Carboxylic Acid

该化合物是一种合成三丁基化合物,产自叶酸,以其强效抗氧化剂和抗炎特性而著称,主要通过激活Nrf2路径发挥作用,该路径管理抗氧化性压力和炎症的细胞防御机制.该化合物在针对慢性肾病,肺动脉高血压和某些癌症等疾病的临床前和临床研究中显示出了希望.它调节对红氧化敏感的信号路径的能力使得它成为治疗应用的宝贵选择,因为氧化性损害和炎症是主要病理驱动因素.巴多克斯酮独特的行动机制和广泛的治疗潜力强调了其在生物医学研究和药物开发中的重要性.

结构式图片

相似化合物

229019-44-7 10106-41-9 61919-52-6

上下游产品

CAS号218600-53-4 甲基巴多索隆 | CAS号65023-19-0 Methyl (3α,5ξ,1... | CAS号65023-20-3 (4AS,6AR,6BS,10... | CAS号218600-50-1 3,12-二氧代齐墩果-9(1... | CAS号218600-52-3 (4AS,6AR,6BS,13... | CAS号305818-39-7 Methyl (2E,5ξ,1... | CAS号305818-40-0 Methyl (5ξ,18α)... | CAS号1707-75-1 1,1-二苯基-2-苦味酰肼

合成工艺路线路线简述

  • 合成目标产物 Bardoxolone 主要起始原料 Oleanolic Acid
  • (文献来源)合成步骤主要原料 Oleanolic Acid
Methyl (4As,6Ar,6Bs,8Ar,12As,14Ar,14Bs)-11-Formyl-2,2,6A,6B,9,9,12A-Heptamethyl-10,14-Dioxo-1,3,4,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B-octadecahydropicene-4A(2H)-Carboxylate置于苯基氯化硒,盐酸羟胺,Sodium Methylate,Lithium Iodide体系中,用 甲醇,乙醚,乙醇,水,乙酸乙酯,N,N-二甲基甲酰胺 用作溶剂,化学反应生成2-氰基-3,12-二氧代齐墩果-1,9-二烯-28-酸
参考文献:Therapeutic Compounds And Methods Of Use
标题:Therapeutic Compounds And Methods Of Use
摘要:化合物和方法可用于化学预防治疗诸如癌症,阿尔茨海默病,帕金森病,炎症性肠病和多发性硬化等疾病.

专利信息


专利号:WO-2023213264-A1
优先权日:2022-05-05
标 题 :Synthesis of amide compound and use thereof
发明人:WANG ZHAOYIN; ZHANG JIAN; CAO JINRUI
权利人:SHANGHAI INST ORGANIC CHEMISTRY CAS
摘要:The present invention relates to a novel oleanamide derivative for activating a KEAP/NRF2/ARE signaling pathway. The compound of the present invention is represented by general formula (I), wherein L, R 3 , R 4 , Z, and n are set forth in the description specification and the claims. Also disclosed are a method for preparing the compound represented by general formula I and an activity test result thereof for activating the KEAP/NRF2/ARE signaling pathway. The compound represented by general formula (I) of the present invention can be used for treating and preventing multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Friedreich's ataxia (FRDA), spinal muscular atrophy (SMA), neuromyelitis optica (NMO), spinocerebellar ataxia (SCA), and other neurodegenerative diseases, and can also be used for treating cerebral apoplexy, autoimmune diseases, diabetes, kidney diseases, and other chronic diseases.

专利号:US-9750749-B2
优先权日:2010-05-03
标题 :Methods of treating thyroid eye disease
发明人:PHIPPS RICHARD P; GUO NAXIN; FELDON STEVEN
权利人:PHIPPS RICHARD P; GUO NAXIN; FELDON STEVEN; UNIV ROCHESTER
摘要:The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions that includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.

专利号:US-8067394-B2
优先权日:2006-11-17
标 题:Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
发明人:HONDA TADASHI; SUNDARARAJAN CHITRA; GRIBBLE GORDON W; SPORN MICHAEL B; LIBY KAREN T
权利人:HONDA TADASHI; SUNDARARAJAN CHITRA; GRIBBLE GORDON W; SPORN MICHAEL B; LIBY KAREN T; DARTMOUTH COLLEGE
摘要:This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-γ, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.

专利号:CN-117050134-A
优先权日:2022-05-05
标 题 :Synthesis of amide compounds and their uses

专利号:CN-108434151-A
优先权日:2008-01-11
标题 :Synthesis of triterpenoids and method for treating diseases

专利号:CN-104739841-B
优先权日:2008-01-11
标题:Synthesis of triterpenoids and method for treating diseases
上海喀露蓝科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.caerulumpharma.com
电话: 18149758185 18149758185👤
📞上海喀露蓝科技有限公司 ⚠️参考联系方式

销售电话:18149758185 18149758185
邮箱:sales-cpd@caerulumpharma.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Hermann C, Lang S, Popp T, Hafner S, Steinritz D, Rump A, Port M, Eder S. Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells. Front Pharmacol. 2021 Jan 29;11:607580. doi: 10.3389/fphar.2020.607580.
2: Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of Diabetic Kidney Disease: Current and Future. Diabetes Metab J. 2021 Jan;45(1):11-26. doi: 10.4093/dmj.2020.0217. Epub 2021 Jan 22.
3: Pedrosa AL, Bitencourt L, Paranhos RM, Leitão CA, Ferreira GC, Simões E Silva AC. Alport Syndrome: a comprehensive review on genetics, pathophysiology, histology, clinical, and therapeutic perspectives. Curr Med Chem. 2021 Jan 7. doi: 10.2174/0929867328666210108113500. Epub ahead of print.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知